About the study

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:

1. Documented diagnosis of multiple myeloma (MM) and measurable disease
2. Documented disease progression during or after their last antimyeloma regimen
3. Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen

Exclusion criteria

1. Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis
2. Known central nervous system (CNS) involvement with myeloma
3. Received immunosuppressive medication within the last 14 days of initiating study treatment
4. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment Other protocol-defined inclusion/exclusion criteria apply

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.